Barinthus Biotherapeutics (BRNS) Q2 2025 earnings summary

Executive summary

• Focus shifted to immunology and inflammation (I&I) pipeline, prioritizing VTP-1000 for celiac disease and deprioritizing infectious disease and oncology programs, with workforce reductions and resource reallocation announced in January 2025.

• VTP-1000 Phase 1 AVALON trial progressing, with final SAD cohort dosed, MAD portion initiated in July 2025, and no treatment-related serious adverse events; SAD data expected early Q4 2025, MAD data mid-2026.

• Completed Phase 1 trial of VTP-850 in prostate cancer, showing encouraging immunogenicity and no treatment-related SAEs.

• Ongoing search for partners to continue development of VTP-300 for hepatitis B, VTP-850, and other viral vector assets; winding down CEPI-funded MERS program.

• Corporate restructuring and pipeline prioritization ongoing.

Financial highlights

• Net loss of $21.1 million for Q2 2025, up from $16.9 million in Q2 2024 and $19.7 million in Q1 2025; six-month net loss of $40.8 million, up from $32.5 million year-over-year.

• Cash, cash equivalents, and restricted cash totaled $87.8 million as of June 30, 2025, down from $112.4 million at year-end 2024 and $100.6 million at March 31, 2025.

• Revenue primarily from research incentives and grants; other operating income decreased due to reduced CEPI funding utilization.

• Research and development expenses were $8.0 million in Q2 2025, down from $11.7 million in Q2 2024 and $8.3 million in Q1 2025, reflecting pipeline prioritization and workforce reduction.

• General and administrative expenses increased to $15.4 million in Q2 2025 from $7.2 million in Q2 2024 and $12.6 million in Q1 2025, mainly due to $8.0 million in foreign exchange losses.

Outlook and guidance

• Cash runway expected to fund operations and capital expenditures into early 2027, but continued losses and negative cash flows anticipated for the foreseeable future.

• Additional funding may be required to advance pipeline and support commercialization; potential sources include equity, debt, or strategic partnerships.

• R&D expenses for legacy infectious disease and oncology programs expected to decrease as trials complete; autoimmune program expenses to continue or increase.

• SAD data from the AVALON trial expected early Q4 2025; MAD data anticipated mid-2026.